Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

381

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasm
Fallopian Tube Neoplasms
Peritoneal Neoplasms

Interventions

DRUG: Nab-paclitaxel 80 mg/m^2
DRUG: Relacorilant 150 mg once daily (QD)
DRUG: Nab-paclitaxel 100 mg/m^2

Sponsor

Corcept Therapeutics

Collaborators

[object Object]